Roflumilast (ALTANA Pharma AG), a phosphodiesterase-4 (PDE4) inhibitor, is being developed for the management of chronic obstructive pulmonary disease (COPD) and asthma. Its once-daily oral ...
Expert Rev Resp Med. 2008;2(5):539-549. Results from human subjects have also demonstrated significant pulmonary anti-inflammatory effects of roflumilast. In a randomized, placebo-controlled ...
About ZORYVE ® ZORYVE (roflumilast) is a potent and selective topical PDE4 inhibitor. PDE4 – an established target in dermatology – is an intracellular enzyme that increases the production of ...
GlobalData on MSN1mon
Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitisArcutis Biotherapeutics' subsidiary, Arcutis Canada, has received Health Canada's approval for ZORYVE (roflumilast) topical ...
Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical foam 0.3%, and $2.5M for ZORYVE cream 0.15% ...
ZORYVE (roflumilast) is a potent and selective topical PDE4 inhibitor. PDE4 - an established target in dermatology - is an intracellular enzyme that increases the production of pro-inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback